VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Liso-cel for second-line R/R aggressive large B-cell NHL

Nilanjan Ghosh MD, PhD, of Levine Cancer Institute, Charlotte, NC, updates us on results of the TRANSCEND-PILOT-017006 study (NCT03483103) investigating lisocabtagene maraleucel (liso-cel), a CD19 directed CAR-T cell therapy, for the treatment of second-line, transplant-ineligible relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter